InvestingPro analysis reveals that Amgen has maintained a robust gross profit margin of 68.71% and generated substantial levered free cash flow of $10.39 billion over the last twelve months.

InvestingPro analysis reveals that Amgen has maintained a robust gross profit margin of 68.71% and generated substantial levered free cash flow of $10.39 billion over the last twelve months. Looking ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...